Team:Slovenia/SocietyPatients

From 2012.igem.org

(Difference between revisions)
 
(13 intermediate revisions not shown)
Line 2: Line 2:
<head>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
 +
<!-- back to top -->
 +
<div style="position:fixed; bottom:45px; right:30px; width:100px; height:66px; background-color:transparent;">
 +
<a href="#topofthepage">
 +
<table style="background-color:transparent;" onclick="window.location = '#topofthepage'" class="invisible" style="height:100%;">
 +
<tr class="invisible" style="background-color:transparent;">
 +
<td class="invisible" style="background-color:transparent;" valign="center">
 +
<img width="100px" src ="https://static.igem.org/mediawiki/2012/1/14/Svn12_hp_btt.png"></img>
 +
</td></tr></table>
 +
</a>
 +
</div>
<style type="text/css">
<style type="text/css">
Line 11: Line 21:
#mainmenu {background:#fff; width:980px; padding-left:0px; padding-right:0px; padding-top:0px; padding-bottom:0px; margin-top:0px; border-top-left-radius:2px; border-top-right-radius:2px; border-bottom-left-radius:10px; border-bottom-right-radius:10px;  font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size:110%; }
#mainmenu {background:#fff; width:980px; padding-left:0px; padding-right:0px; padding-top:0px; padding-bottom:0px; margin-top:0px; border-top-left-radius:2px; border-top-right-radius:2px; border-bottom-left-radius:10px; border-bottom-right-radius:10px;  font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size:110%; }
-
 
+
p.inliner{text-align:justify; }
 +
img.inliner{width:100%; border-width:0px;}
 +
table.inliner{border-width:0px; float:right; width:60%; margin-bottom:15px; margin-left:15 px; margin-right:15 px; padding-left:15px; }
 +
td.inliner, th.normal { border-width:0px;}
 +
thead.inliner{}
 +
tbody .inliner{}
p {line-height:1.5em; margin:0 0 15px; text-align:justify;}
p {line-height:1.5em; margin:0 0 15px; text-align:justify;}
Line 180: Line 195:
thead.summary{ background:#d0ecf4; color:#000000; border:none; border-radius:0px; }
thead.summary{ background:#d0ecf4; color:#000000; border:none; border-radius:0px; }
tbody.summary{ background: #fff; }
tbody.summary{ background: #fff; }
-
 
Line 201: Line 215:
#cssmenu ul li > ul li{display:block; list-style:inside none; padding:0; margin:0; position:relative;}  
#cssmenu ul li > ul li{display:block; list-style:inside none; padding:0; margin:0; position:relative;}  
#cssmenu ul li > ul li a{ outline:none; display:block; position:relative; margin:0; padding:8px 20px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); }  
#cssmenu ul li > ul li a{ outline:none; display:block; position:relative; margin:0; padding:8px 20px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); }  
 +
#cssmenu ul li > ul li a table tr td span{ outline:none; display:block; position:relative; margin:0; padding:0px 0px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); }
#cssmenu, #cssmenu > ul > li > ul > li a:hover
#cssmenu, #cssmenu > ul > li > ul > li a:hover
{ background:#043A6B;  
{ background:#043A6B;  
Line 216: Line 231:
#cssmenu > ul > li > a:hover{background:#0C5DA5;}  
#cssmenu > ul > li > a:hover{background:#0C5DA5;}  
/* end CSS navigation menu (blue) */
/* end CSS navigation menu (blue) */
 +
 +
/*new table start*/
 +
table.newtable {background-color:transparent;}
 +
td.newtable, th.newtable {background-color:transparent;}
 +
thead.newtable{ }
 +
tbody .newtable{}
 +
/*new table*/
Line 292: Line 314:
<body>
<body>
 +
<a name="topofthepage" style="background-color:transparent;"></a>
<div id="banner">
<div id="banner">
-
<a style="position:absolute; top:0px; left:490px;" href="https://2012.igem.org/Main_Page"><b>iGEM 2012</b></a>
 
</div>
</div>
Line 316: Line 338:
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators'><span>Designed TAL regulators</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators'><span>Designed TAL regulators</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>  
-
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li>  
+
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch';" class="newtable"><tr class="newtable"><td class="newtable"><span>Positive feedback loop switch</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 +
    <li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchControls'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchControls';" class="newtable"><tr class="newtable"><td class="newtable"><span>Controls</span></td><td class="newtable"><img style="margin-right:-81px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>  
  </ul>
  </ul>
</li>
</li>
Line 324: Line 347:
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsEscapeTag'><span>Escape tag</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsEscapeTag'><span>Escape tag</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsTermination'><span>Termination</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsTermination'><span>Termination</span></a></li>  
-
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation'><span>Microcapsule degradation</span></a></li>  
+
    <li><a href="https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation"><table  onclick="window.location = 'https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation';" class="newtable"><tr class="newtable"><td class="newtable"><span>Microcapsule degradation</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>  
  </ul>
  </ul>
</li>
</li>
Line 332: Line 355:
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationHepatitisC'><span>Hepatitis C</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationHepatitisC'><span>Hepatitis C</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationIschaemicHeartDisease'><span>Ischaemic heart disease</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationIschaemicHeartDisease'><span>Ischaemic heart disease</span></a></li>  
 +
    <li><a href='https://2012.igem.org/Team:Slovenia/ImplementationImpact'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ImplementationImpact';" class="newtable"><tr class="newtable"><td class="newtable"><span>Impact</span></td><td class="newtable"><img style="margin-right:-86px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 
 
  </ul>
  </ul>
Line 339: Line 363:
  <ul>
  <ul>
<li><a href='https://2012.igem.org/Team:Slovenia/Modeling'><span>Overview</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/Modeling'><span>Overview</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingPK'><span>Pharmacokinetics</span></a></li>
+
    <li><a href='https://2012.igem.org/Team:Slovenia/ModelingPK'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingPK';" class="newtable"><tr class="newtable"><td class="newtable"><span>Pharmacokinetics</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMethods'><span>Modeling methods</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMethods'><span>Modeling methods</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel'><span>Quantitative and stability model</span></a></li>  
+
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel';" class="newtable"><tr class="newtable"><td class="newtable"><span>Experimental model</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>  
-
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations'><span>Interactive simulations</span></a></li>
+
    <li><a href='https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations';" class="newtable"><tr class="newtable"><td class="newtable"><span>Interactive simulations</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
  </ul>
  </ul>
</li>
</li>
Line 355: Line 379:
  <ul>
  <ul>
<li><a href='https://2012.igem.org/Team:Slovenia/Notebook'><span>Experimental methods</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/Notebook'><span>Experimental methods</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/NotebookLablog'><span>Lablog</span></a></li>
+
    <li><a href='https://2012.igem.org/Team:Slovenia/NotebookLablog'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/NotebookLablog';" class="newtable"><tr class="newtable"><td class="newtable"><span>Lablog</span></td><td class="newtable"><img style="margin-right:-90px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/NotebookLabSafety'><span>Lab safety</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/NotebookLabSafety'><span>Lab safety</span></a></li>  
  </ul>
  </ul>
Line 378: Line 402:
<li><a href='https://2012.igem.org/Team:Slovenia/Team'><span>Team members</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/Team'><span>Team members</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TeamAttributions'><span>Attributions</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TeamAttributions'><span>Attributions</span></a></li>
 +
<li><a href='https://2012.igem.org/Team:Slovenia/TeamCollaborations'><table  onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TeamCollaborations';" class="newtable"><tr class="newtable"><td class="newtable"><span>Collaborations</span></td><td class="newtable"><img style="margin-right:-20px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TeamGallery'><span>Gallery</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TeamGallery'><span>Gallery</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TeamSponsors'><span>Sponsors</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TeamSponsors'><span>Sponsors</span></a></li>  
Line 385: Line 410:
</div>
</div>
<!-- end main menu -->
<!-- end main menu -->
 +
</div> <!-- end menu -->
</div> <!-- end menu -->
Line 393: Line 419:
<!-- VSEBINA OD TU DALJE -->
<!-- VSEBINA OD TU DALJE -->
<h1>Patients</h1>
<h1>Patients</h1>
-
<p>We are aware that general acceptance of the use of synthetic biology in everyday life may sometimes be an issue in the society. We wondered if the perception of the applications of synthetic biology use is different when it comes to medical problems. We prepared a questionnaire about the use of new therapeutic systems for biopharmaceuticals for patients with hepatitis C (link: Questionnaire). We asked them on their perception of the potential medical application of our designed therapy and their views on synthetic biology. The majority of them expressed the enthusiasm for the medical application of our ideas and a surprising half of them were willing participate in a potential clinical study. </p>
+
<br />
 +
 
 +
 
 +
<!-- dummy link na bannerju -->
 +
<a href="https://2012.igem.org/Main_Page">
 +
<div id="dummy" style="background-color:transparent; position:absolute; left:870px; top:25px; width:115px; height:80px; z-index:100; opacity:0.0;">
 +
</div>
 +
</a>
 +
 
 +
 
 +
<table class="summary">
 +
<tbody class="summary">
 +
<tr class="summary">
 +
<td class="summary">
 +
<p>We are aware that general acceptance of the use of synthetic biology in everyday life may sometimes be an issue in the society. We prepared a <a href="https://2012.igem.org/Team:Slovenia/SocietyQuestionnaire">questionnaire</a> about the use of new therapeutic systems for biopharmaceuticals for patients with hepatitis C. We asked them about their perception of the potential medical application of our designed therapy and their views on synthetic biology. The majority of them expressed enthusiasm for the medical application of our ideas and half of them would be willing to participate in a potential clinical study of this type of therapy.</p>
 +
</td>
 +
</tr>
 +
</tbody>
 +
</table>
 +
 
 +
<p>The questionnaire for <b>patients with hepatitis C</b> was distributed among the patients who are receiving the interferon therapy at <b>the Clinic for Infectious Diseases and Febrile Illnesses at the University Medical Centre Ljubljana</b> (Figure 1). We discussed with the patients in person, explained them the idea of our project and asked them to participate in our survey. </p>
-
<p>The questionnaire for <b>patients with hepatitis C</b> was distributed among the patients who are on the interferon therapy and were at <b>the Department of Infectious Diseases at the University Medical Centre Ljubljana</b> at the time (Figure 1). We discussed in person with patients, explained them the idea of our project and asked them if they would be willing to participate in our survey. </p>
 
-
<img src="X"></img>
 
-
<p><b>Figure 1. Team members Zala and Fedja in the examination room with Jelka Megliè Volkar, MD, a specialist infectologist (first from the left).</b></p>
 
<br/>
<br/>
-
<p><b>24 patients infected with hepatitis C</b> filled out the questionnaire. The majority of them were men (67%) and the average age of patients was 45 years. Half of the patients graduated from high school, 29% finished only primary school and 21% of patients had a university degree. </p>
+
<p>
-
<p>The number of patients participating in the survey was small therefore we cannot draw any strong conclusions from the results, however they do provide some interesting results. A comparison of all the results of our survey including the general (mostly student) population and journalists can be found here: link: Media and general public. </p>
+
<!-- inline figure 1 -->
-
<p>59% of patients reported mild (34%) or strong (25%) <b>side effects</b> and only 8% of patients had no side effects (Figure 2, left). 4% of the patients felt that <b>the need for the regular subcutaneous application of interferon</b> has a strong influence on the quality of their life, 63% of patients felt this has medium influence and 33% of the patients felt that this type of application has no influence (Figure 2, right). The majority (71%) of patients felt that it would be a good idea to invent a new drug delivery system, which would prevent subcutaneous injections of interferon and only one patient disagreed with this. </p>
+
<table class="inliner" style="width:40%;">
-
<img src="X"></img>
+
<tbody  class="inliner">
-
<p><b>Figure 2. Adverse effects of interferon therapy (left) and negative impact of subncutaeous application of interferon on life quality (right). </b></p>
+
<tr class="inliner"><td class="inliner"><img class="inliner" src="https://static.igem.org/mediawiki/2012/b/bc/Svn12_society_patients_fig1.jpg"/></td></tr>
 +
<tr class="inliner"><td class="inliner"><b>Figure 1.</b> 
 +
<b>Team members Zala and Fedja in the examination room with Jelka Meglič Volkar, MD, a specialist infectologist (first from the left).</b> 
 +
</td></tr>
 +
</tbody>
 +
</table>
 +
<!-- end figure 1-->
 +
</p>
 +
<p><b>24 patients infected with hepatitis C</b> filled out the questionnaire. The majority of them were male (67%) and the average age of the patients was 45 years. Half of the patients graduated from high school, 29% finished only primary school and 21% of patients had a university degree. </p>
 +
<p>The number of patients participating in the survey was small therefore we cannot draw any strong conclusions from the results; however they do provide some interesting views. A comparison of all the results of our survey including the general (mostly student) population and journalists can be found here: <a href="https://2012.igem.org/Team:Slovenia/SocietyMedia">Journalists and general public</a>.</p>
 +
<p>59% of the patients reported mild (34%) or strong (25%) <b>side effects</b> and only two patients had no side effects (Figure 2, left). One of the patients felt that <b>the need for the regular subcutaneous application of interferon</b> has a strong influence on the quality of his life, 63% of the patients felt this has medium influence and 33% of the patients felt that this type of application has no influence (Figure 2, right). The majority (71%) of patients felt that it would be a good idea to invent a new drug delivery system, which would prevent subcutaneous injections of interferon and only one patient disagreed with this. </p>
 +
<img src="https://static.igem.org/mediawiki/2012/c/cd/Svn12_society_patients_fig2.png"></img>
 +
<center><p style="width:60%; horizontal-align:center;"><b>Figure 2. Adverse effects of interferon therapy (left) and negative impact of subncutaeous application of interferon on life quality (right). </b></p></center>
<br/>
<br/>
-
<p>The results of our survey showed that patients with hepatitis C showed enthusiasm for this new type of therapy. 71% of them think it would be <b>beneficial to develop a therapywith human cells which would produce biological drugs inside the diseased tissue</b> (link: Media and general public). The <b>most important requirements</b> for this type of therapy are, in the view of patients, efficiency (57%), safety (33%) and price (10%) (Figure 3).  </p>
+
<p>The results of our survey showed that patients with hepatitis C showed enthusiasm for this new type of therapy. 71% of them think it would be <b>beneficial to develop a therapy with human cells which would produce biological drugs inside the diseased tissue</b> (<a href="https://2012.igem.org/Team:Slovenia/SocietyMedia">Journalists and general public</a>, Figure 5). The <b>most important requirements</b> for this type of therapy are, in the view of patients, efficiency (57%), safety (33%) and price (10%) (Figure 3).  </p>
-
<p>Patients are the only group that could provide information on questions related to the specifics of biological therapy. We noticed that a large majority of patients receiving biological therapy exhibits side effects (87%). Injecting biological drugs had in this context only medium effect on the quality of life (Figure 2). </p>
+
 
-
<p>Among the considerations that would affect the application of therapy patients considered as most important efficiency, followed by safety (Figure 3). Price does not seem to be very important issue, which reflects the organisation of health care in Slovenia. It is interesting that patients consider, in contrast to general public, that the access to biological drugs in Slovenia is satisfying (link: Media and general public, Figure 7). </p>
+
<p>
-
<img src="X"></img>
+
<!-- inline figure 1 -->
-
<p><b>Figure 3. Which of the following would be most important for you regarding [a microencapsulated synthetic cellular device] treatment: efficiency, safety, price, ethical considerations? </b></p>
+
<table class="inliner" style="width:40%;">
 +
<tbody  class="inliner">
 +
<tr class="inliner"><td class="inliner"><img class="inliner" src="https://static.igem.org/mediawiki/2012/0/0b/Svn12_society_patients_fig3.png"/></td></tr>
 +
<tr class="inliner"><td class="inliner"><b>Figure 3.</b> 
 +
<b>Which of the following would be most important for you regarding [treatment with microencapsulated synthetic cellular device] treatment: efficiency, safety, price, ethical considerations?</b> 
 +
</td></tr>
 +
</tbody>
 +
</table>
 +
<!-- end figure 1-->
 +
</p>
 +
<p>Patients are the only group that could provide information on questions related to the specifics of their experience with biological therapy. We noticed that a large majority of patients receiving biological therapy exhibits side effects (87%). Injecting biological drugs had in this context only medium effect on the quality of their life (Figure 2). </p>
 +
<p>Among the considerations that would affect the application of therapy, patients considered as most important efficiency, followed by safety (Figure 3). Price does not seem to be a very important issue, which reflects the organization of health care in Slovenia. It is interesting that patients consider, in contrast to the general public, that the access to biological drugs in Slovenia is satisfying (<a href="https://2012.igem.org/Team:Slovenia/SocietyMedia">Journalists and general public</a>, Figure 2). </p>
 +
 
<br/>
<br/>
<p>We were pleased to see that 50% of the questioned patients would be willing to <b>participate in a clinical study of this type of therapy</b>, 37% might consider it and 13% of patients would not be willing to participate (Figure 4, left). Certainly clinical studies could proceed only after stringent preclinical studies would show favorable results and safety of this type of therapy. Involvement of genetic modification as the technique that has a bad connotation in the general public did not sway the majority of patients (70%) to change their previous answer from yes or maybe to no (Figure 4, right).  </p>
<p>We were pleased to see that 50% of the questioned patients would be willing to <b>participate in a clinical study of this type of therapy</b>, 37% might consider it and 13% of patients would not be willing to participate (Figure 4, left). Certainly clinical studies could proceed only after stringent preclinical studies would show favorable results and safety of this type of therapy. Involvement of genetic modification as the technique that has a bad connotation in the general public did not sway the majority of patients (70%) to change their previous answer from yes or maybe to no (Figure 4, right).  </p>
-
<img src="X"></img>
+
<img src="https://static.igem.org/mediawiki/2012/4/4b/Svn12_society_patients_fig4.png"></img>
-
<p><b>Figure 4. Would you participate in study using that kind of therapy? (left) Would you change your previous answer from yes/maybe to no, if you knew that these cells are modified in laboratories? (right) </b></p>
+
<center><p style="width:60%; horizontal-align:center;"><b>Figure 4. Would you participate in study using that kind of therapy? (left) Would you change your previous answer from yes/maybe to no, if you knew that these cells are modified in laboratories? (right) </b></p></center>
<br/>
<br/>
 +
 +
 +
 +
<hr>
 +
<b>
 +
Next: <a href='https://2012.igem.org/Team:Slovenia/SocietyMedia'>Journalists and general public >></a>
 +
</b>

Latest revision as of 20:58, 26 October 2012


Patients


We are aware that general acceptance of the use of synthetic biology in everyday life may sometimes be an issue in the society. We prepared a questionnaire about the use of new therapeutic systems for biopharmaceuticals for patients with hepatitis C. We asked them about their perception of the potential medical application of our designed therapy and their views on synthetic biology. The majority of them expressed enthusiasm for the medical application of our ideas and half of them would be willing to participate in a potential clinical study of this type of therapy.

The questionnaire for patients with hepatitis C was distributed among the patients who are receiving the interferon therapy at the Clinic for Infectious Diseases and Febrile Illnesses at the University Medical Centre Ljubljana (Figure 1). We discussed with the patients in person, explained them the idea of our project and asked them to participate in our survey.


Figure 1. Team members Zala and Fedja in the examination room with Jelka Meglič Volkar, MD, a specialist infectologist (first from the left).

24 patients infected with hepatitis C filled out the questionnaire. The majority of them were male (67%) and the average age of the patients was 45 years. Half of the patients graduated from high school, 29% finished only primary school and 21% of patients had a university degree.

The number of patients participating in the survey was small therefore we cannot draw any strong conclusions from the results; however they do provide some interesting views. A comparison of all the results of our survey including the general (mostly student) population and journalists can be found here: Journalists and general public.

59% of the patients reported mild (34%) or strong (25%) side effects and only two patients had no side effects (Figure 2, left). One of the patients felt that the need for the regular subcutaneous application of interferon has a strong influence on the quality of his life, 63% of the patients felt this has medium influence and 33% of the patients felt that this type of application has no influence (Figure 2, right). The majority (71%) of patients felt that it would be a good idea to invent a new drug delivery system, which would prevent subcutaneous injections of interferon and only one patient disagreed with this.

Figure 2. Adverse effects of interferon therapy (left) and negative impact of subncutaeous application of interferon on life quality (right).


The results of our survey showed that patients with hepatitis C showed enthusiasm for this new type of therapy. 71% of them think it would be beneficial to develop a therapy with human cells which would produce biological drugs inside the diseased tissue (Journalists and general public, Figure 5). The most important requirements for this type of therapy are, in the view of patients, efficiency (57%), safety (33%) and price (10%) (Figure 3).

Figure 3. Which of the following would be most important for you regarding [treatment with microencapsulated synthetic cellular device] treatment: efficiency, safety, price, ethical considerations?

Patients are the only group that could provide information on questions related to the specifics of their experience with biological therapy. We noticed that a large majority of patients receiving biological therapy exhibits side effects (87%). Injecting biological drugs had in this context only medium effect on the quality of their life (Figure 2).

Among the considerations that would affect the application of therapy, patients considered as most important efficiency, followed by safety (Figure 3). Price does not seem to be a very important issue, which reflects the organization of health care in Slovenia. It is interesting that patients consider, in contrast to the general public, that the access to biological drugs in Slovenia is satisfying (Journalists and general public, Figure 2).


We were pleased to see that 50% of the questioned patients would be willing to participate in a clinical study of this type of therapy, 37% might consider it and 13% of patients would not be willing to participate (Figure 4, left). Certainly clinical studies could proceed only after stringent preclinical studies would show favorable results and safety of this type of therapy. Involvement of genetic modification as the technique that has a bad connotation in the general public did not sway the majority of patients (70%) to change their previous answer from yes or maybe to no (Figure 4, right).

Figure 4. Would you participate in study using that kind of therapy? (left) Would you change your previous answer from yes/maybe to no, if you knew that these cells are modified in laboratories? (right)



Next: Journalists and general public >>